Product Information
INSULIN GLARGINE SOLOSTAR U300 is a generic product labeled by Sanofi-Aventis U.S. LLC, priced at $27.0054 per ML under NDC 00955390003. Its NADAC has been published 116 times since Apr 17, 2024.
Strength
300 [iU]/mL
Manufacturer
Sanofi-Aventis U.S. LLCNDC
00955390003
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
INSULIN GLARGINEApproval Type
Biologic (BLA)
FDA Application
BLA206538On Market Since
4/1/2023
Pharmacological Classes
Price Statistics
The NADAC for INSULIN GLARGINE SOLOSTAR U300 has been published 116 times since Apr 17, 2024, and over the history we have for it it has declined 26.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $27.0054 per ML |
|---|---|
| All-time high | $36.8236 (May 15, 2024) |
| All-time low | $26.9353 (Apr 22, 2026) |
| 52-week high | $36.7049 |
| 52-week low | $26.9353 |
| Median price | $36.6328 |
| Average price | $34.6564 |
| Largest weekly change | -26.4% (Apr 22, 2026) |
| Weeks tracked | 116 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sanofi-Aventis U.S. LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
insulin glargine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Insulin Analog class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of INSULIN GLARGINE SOLOSTAR U300?
The current National Average Drug Acquisition Cost (NADAC) for INSULIN GLARGINE SOLOSTAR U300, manufactured by Sanofi-Aventis U.S. LLC, is $27.0054 per ML (NDC 00955390003), effective Sep 30, 2026.
How has the price of INSULIN GLARGINE SOLOSTAR U300 changed over time?
Over the history we have for it, the NADAC for INSULIN GLARGINE SOLOSTAR U300 has declined 26.7%. It has been tracked across 116 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for INSULIN GLARGINE SOLOSTAR U300?
Since Apr 17, 2024, the NADAC for INSULIN GLARGINE SOLOSTAR U300 has ranged from a low of $26.9353 (Apr 22, 2026) to a high of $36.8236 (May 15, 2024), with a median of $36.6328 per ML.
Are there cheaper alternatives to INSULIN GLARGINE SOLOSTAR U300?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as INSULIN GLARGINE SOLOSTAR U300 in a comparable dosage form, but none are currently priced below it.
Who manufactures INSULIN GLARGINE SOLOSTAR U300?
INSULIN GLARGINE SOLOSTAR U300 (NDC 00955390003) is labeled by Sanofi-Aventis U.S. LLC, and CMS classifies it as a generic product.